Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
2.

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.

Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1442-1450. doi: 10.6004/jnccn.2018.7074.

PMID:
30545991
3.

Recent advances in non-surgical management of cancer in the elderly.

Guerard EJ, Harmon GE, Sahasrabudhe KD, LoConte NK.

F1000Res. 2018 Nov 15;7. pii: F1000 Faculty Rev-1793. doi: 10.12688/f1000research.14264.1. eCollection 2018. Review.

4.

Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.

Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):262-279. doi: 10.1200/EDBK_200939. Review.

PMID:
30231359
5.

Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction.

LoConte NK, Gershenwald JE, Thomson CA, Crane TE, Harmon GE, Rechis R.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):88-100. doi: 10.1200/EDBK_200093. Review.

PMID:
30231343
6.

Alcohol and Cancer: A Statement of the American Society of Clinical Oncology.

LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ.

J Clin Oncol. 2018 Jan 1;36(1):83-93. doi: 10.1200/JCO.2017.76.1155. Epub 2017 Nov 7.

PMID:
29112463
7.

Working to Increase Vaccination for Human Papillomavirus: A Survey of Wisconsin Stakeholders, 2015.

Mroz S, Zhang X, Williams M, Conlon A, LoConte NK.

Prev Chronic Dis. 2017 Sep 28;14:E85. doi: 10.5888/pcd14.160610.

8.

Increasing Colorectal Cancer Screening at an Urban FQHC Using iFOBT and Patient Navigation.

Martin RL, Tully M, Kos A, Frazer D, Williamson A, Conlon A, Enser JJ, LoConte NK.

Health Promot Pract. 2017 Sep;18(5):741-750. doi: 10.1177/1524839917705127.

PMID:
28812930
9.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
10.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.

Engle JA, Traynor AM, Campbell TC, Wisinski KB, LoConte N, Liu G, Wilding G, Kolesar JM.

J Oncol Pharm Pract. 2018 Jul;24(5):348-353. doi: 10.1177/1078155217704989. Epub 2017 Apr 29.

11.

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.

Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS.

J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6.

12.

Cancer-related cognitive impairment and its relation to PTSD.

Robins HI, Johnson L, LoConte N, Brandt K.

Breast. 2017 Aug;34:134. doi: 10.1016/j.breast.2017.03.005. Epub 2017 Mar 9. No abstract available.

PMID:
28285890
13.

Utilization of preoperative endoscopic ultrasound for pancreatic adenocarcinoma.

Schmocker RK, Vanness DJ, Greenberg CC, Havlena JA, LoConte NK, Weiss JM, Neuman HB, Leverson G, Smith MA, Winslow ER.

HPB (Oxford). 2017 May;19(5):465-472. doi: 10.1016/j.hpb.2017.01.017. Epub 2017 Feb 23.

14.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.

Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA.

Clin Colon Rectal Surg. 2016 Sep;29(3):232-8. doi: 10.1055/s-0036-1584292. Review.

15.

Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP.

JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137. Epub 2016 Aug 17.

16.

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

Jin N, Lubner SJ, Mulkerin DL, Rajguru S, Carmichael L, Chen H, Holen KD, LoConte NK.

Oncologist. 2016 Jul;21(7):785-6. doi: 10.1634/theoncologist.2016-0060. Epub 2016 Jun 3.

17.

The Role of Intraoperative Pathologic Assessment in the Surgical Management of Ductal Carcinoma In Situ.

Decker MR, Trentham-Dietz A, Loconte NK, Neuman HB, Smith MA, Punglia RS, Greenberg CC, Wilke LG.

Ann Surg Oncol. 2016 Sep;23(9):2788-94. doi: 10.1245/s10434-016-5192-5. Epub 2016 Mar 29.

18.

Use of a novel statistical technique to examine the delivery of breast cancer follow-up care by different types of oncology providers.

Neuman HB, Rathouz PJ, Winslow E, Weiss JM, LoConte NK, Lin CP, Wurm M, Smith MA, Schrag D, Greenberg CC.

J Eval Clin Pract. 2016 Oct;22(5):737-44. doi: 10.1111/jep.12529. Epub 2016 Mar 17.

19.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G.

Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14.

20.

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.

Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL.

Pancreas. 2016 Mar;45(3):370-5. doi: 10.1097/MPA.0000000000000458.

21.

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA.

Ther Adv Med Oncol. 2015 Sep;7(5):252-62. doi: 10.1177/1758834015591952. Review.

22.

A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.

Makielski RJ, Lubner SJ, Mulkerin DL, Traynor AM, Groteluschen D, Eickhoff J, LoConte NK.

Cancer Chemother Pharmacol. 2015 Aug;76(2):317-23. doi: 10.1007/s00280-015-2783-y. Epub 2015 Jun 12.

PMID:
26068189
23.

A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G.

Invest New Drugs. 2015 Feb;33(1):169-76. doi: 10.1007/s10637-014-0166-6. Epub 2014 Oct 17.

24.

Mailed invitations for colorectal screening are effective in increasing screening participation in uninsured adults with faecal immunochemical testing: the preferred screening modality.

LoConte NK, Deming DA.

Evid Based Med. 2014 Aug;19(4):145. doi: 10.1136/eb-2014-101772. Epub 2014 Apr 12. No abstract available.

PMID:
24727711
25.

Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.

Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO, Loconte NK, Greenberg CC, Smith MA.

Ann Surg Oncol. 2014 Jun;21(6):1781-91. doi: 10.1245/s10434-014-3631-8. Epub 2014 Mar 19.

26.

Determining breast cancer axillary surgery within the surveillance epidemiology and end results-Medicare database.

Schmocker RK, Caretta-Weyer H, Weiss JM, Ronk K, Havlena J, Loconte NK, Decker M, Smith MA, Greenberg CC, Neuman HB.

J Surg Oncol. 2014 Jun;109(8):756-9. doi: 10.1002/jso.23579. Epub 2014 Mar 18.

27.

Engaging health systems to increase colorectal cancer screening: community-clinical outreach in underserved areas of Wisconsin.

LoConte NK, Weeth-Feinstein L, Conlon A, Scott S.

Prev Chronic Dis. 2013 Nov 21;10:E192. doi: 10.5888/pcd10.130180.

28.

Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.

Caretta-Weyer H, Greenberg CG, Wilke LG, Weiss J, LoConte NK, Decker M, Steffens NM, Smith MA, Neuman HB.

Ann Surg Oncol. 2013 Dec;20(13):4145-52. doi: 10.1245/s10434-013-3193-1.

29.

Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors.

Neuman HB, Weiss JM, Schrag D, Ronk K, Havlena J, LoConte NK, Smith MA, Greenberg CC.

Ann Surg Oncol. 2013 Dec;20(13):4128-36. doi: 10.1245/s10434-013-3170-8. Epub 2013 Aug 14.

30.

Predictors of short-term postoperative survival after elective colectomy in colon cancer patients ≥ 80 years of age.

Neuman HB, Weiss JM, Leverson G, O'Connor ES, Greenblatt DY, Loconte NK, Greenberg CC, Smith MA.

Ann Surg Oncol. 2013 May;20(5):1427-35. doi: 10.1245/s10434-012-2721-8. Epub 2013 Jan 5.

31.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ.

Invest New Drugs. 2013 Aug;31(4):943-8. doi: 10.1007/s10637-012-9916-5. Epub 2012 Dec 21.

32.

Characterizing the psychological distress response before and after a cancer diagnosis.

Schumacher JR, Palta M, Loconte NK, Trentham-Dietz A, Witt WP, Heidrich SM, Smith MA.

J Behav Med. 2013 Dec;36(6):591-600. doi: 10.1007/s10865-012-9453-x. Epub 2012 Aug 28.

33.

Surgical treatment of colon cancer in patients aged 80 years and older : analysis of 31,574 patients in the SEER-Medicare database.

Neuman HB, O'Connor ES, Weiss J, Loconte NK, Greenblatt DY, Greenberg CC, Smith MA.

Cancer. 2013 Feb 1;119(3):639-47. doi: 10.1002/cncr.27765. Epub 2012 Aug 14.

34.

A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.

Frank D, Jumonville A, Loconte NK, Schelman WR, Mulkerin D, Lubner S, Richter K, Winterle N, Wims MB, Dietrich L, Winkler JM, Volk M, Kim K, Holen KD.

J Gastrointest Oncol. 2012 Jun;3(2):90-6. doi: 10.3978/j.issn.2078-6891.2011.049.

35.

Cancer screening of long-term cancer survivors.

Schumacher JR, Witt WP, Palta M, Loconte NK, Heidrich SM, Trentham-Dietz A, Pandhi N, Smith MA.

J Am Board Fam Med. 2012 Jul-Aug;25(4):460-9. doi: 10.3122/jabfm.2012.04.110118.

36.

Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data.

Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G, Smith MA.

J Clin Oncol. 2011 Nov 20;29(33):4401-9. doi: 10.1200/JCO.2011.36.4414. Epub 2011 Oct 3.

37.

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA.

J Clin Oncol. 2011 Sep 1;29(25):3381-8. doi: 10.1200/JCO.2010.34.3426. Epub 2011 Jul 25.

38.

Increasing Disparity in Colorectal Cancer Incidence and Mortality Among African Americans and Whites: A State's Experience.

Loconte NK, Williamson A, Gayle A, Weiss J, Leal T, Cetnar J, Mohammed T, Tevaarwerk A, Jones N.

J Gastrointest Oncol. 2011;2(2):85-92. No abstract available.

39.

A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, Eickhoff J, Chen H, Loconte NK.

Oncologist. 2011;16(6):835-43. doi: 10.1634/theoncologist.2011-0031. Epub 2011 May 31.

40.

Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.

O'Mahar SE, Campbell TC, Hoang T, Seo S, Kim K, Larson MM, Marcotte SM, LoConte NK, Traynor AM.

J Thorac Oncol. 2011 May;6(5):951-3. doi: 10.1097/JTO.0b013e31820db227.

41.

A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.

Dennie TW, Fleming RA, Bowen CJ, Dar MM, Alberti D, Oliver K, Loconte N, Mulkerin D, Holen KD.

Clin Colorectal Cancer. 2011 Mar 1;10(1):57-62. doi: 10.3816/CCC.2011.n.008.

PMID:
21609937
42.

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.

Cetnar J, Wilding G, McNeel D, LoConte NK, McFarland TA, Eickhoff J, Liu G.

Urol Oncol. 2013 May;31(4):436-41. doi: 10.1016/j.urolonc.2011.02.007. Epub 2011 Apr 11.

43.

Persistence in breast cancer disparities between African Americans and whites in Wisconsin.

Lepeak L, Tevaarwerk A, Jones N, Williamson A, Cetnar J, LoConte N.

WMJ. 2011 Feb;110(1):21-5.

44.

A preclinical and clinical study of lithium in low-grade neuroendocrine tumors.

Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H.

Oncologist. 2011;16(4):452-7. doi: 10.1634/theoncologist.2010-0323. Epub 2011 Mar 10.

45.

Optimizing surgical care of colon cancer in the older adult population.

Kennedy GD, Rajamanickam V, O'connor ES, Loconte NK, Foley EF, Leverson G, Heise CP.

Ann Surg. 2011 Mar;253(3):508-14. doi: 10.1097/SLA.0b013e3181f19518.

46.

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.

Heath EI, Blumenschein GR Jr, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G.

Cancer Chemother Pharmacol. 2011 Sep;68(3):703-12. doi: 10.1007/s00280-010-1536-1. Epub 2010 Dec 8.

47.

A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL.

Clin Colorectal Cancer. 2010 Jul;9(3):157-61. doi: 10.3816/CCC.2010.n.021.

48.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD.

J Clin Oncol. 2010 Jul 20;28(21):3491-7. doi: 10.1200/JCO.2010.28.4075. Epub 2010 Jun 7.

49.

Readmission after colectomy for cancer predicts one-year mortality.

Greenblatt DY, Weber SM, O'Connor ES, LoConte NK, Liou JI, Smith MA.

Ann Surg. 2010 Apr;251(4):659-69. doi: 10.1097/SLA.0b013e3181d3d27c.

50.

Perceived stigma, self-blame, and adjustment among lung, breast and prostate cancer patients.

Else-Quest NM, LoConte NK, Schiller JH, Hyde JS.

Psychol Health. 2009 Oct;24(8):949-64. doi: 10.1080/08870440802074664.

PMID:
20205038

Supplemental Content

Loading ...
Support Center